This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (533)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Pierre L. Le Bars, MD, PhD; Martin M. Katz, PhD; Nancy Berman, PhD; Turan M. Itil, MD; Alfred M. Freedman, MD; Alan F. Schatzberg, MD

JAMA. 1997;278(16):1327-1332.

Abstract
Context.
—EGb 761 is a particular extract of Ginkgo biloba used in Europe to alleviate symptoms associated with numerous cognitive disorders. Its use in dementias is based on positive results from only a few controlled clinical trials, most of which did not include standard assessments of cognition and behavior.

Objective.
—To assess the efficacy and safety of EGb in Alzheimer disease and multi-infarct dementia.

Design.
—A 52-week, randomized double-blind, placebo-controlled, parallelgroup, multicenter study.

Patients.
—Mildly to severely demented outpatients with Alzheimer disease or multi-infarct dementia, without other significant medical conditions.

Intervention.
—Patients assigned randomly to treatment with EGb (120 mg/d) or placebo. Safety, compliance, and drug dispensation were monitored every 3 months with complete outcome evaluation at 12, 26, and 52 weeks.

Primary Outcome Measures.
—Alzheimer's Disease Assessment Scale—Cognitive subscale (ADAS-Cog), Geriatric Evaluation by Relative's Rating Instrument (GERRI), and Clinical Global Impression of Change (CGIC).

Results.
—From 309 patients included in an intent-to-treat analysis, 202 provided evaluable data for the 52-week end point analysis. In the intent-to-treat analysis, the EGb group had an ADAS-Cog score 1.4 points betterthan the placebo group (P=.04) and a GERRI score 0.14 points better than the placebo group (P=.004). The same patterns were observed with the evaluable data set in which 27% of patients treated with EGb achieved at least a 4-point improvement on the ADAS-Cog, compared with 14% taking placebo (P=.005); on the GERRI, 37% were considered improved with EGb, compared with 23% taking placebo (P=.003). No difference was seen in the CGIC. Regarding the safety profile of EGb, no significant differences compared with placebo were observed in the number of patients reporting adverse events or in the incidence and severity of these events.

Conclusions.
—EGb was safe and appears capable of stabilizing and, in a substantial number of cases, improving the cognitive performance and the social functioning of demented patients for 6 months to 1 year. Although modest, the changes induced by EGb were objectively measured by the ADAS-Cog and were of sufficient magnitude to be recognized by the caregivers in the GERRI.

Author Affiliations
for the North American EGb Study Group

From the New York Institute for Medical Research, Tarrytown (Dr Le Bars); Department of Psychiatry, Albert Einstein College of Medicine-Montefiore Medical Center, New York, NY (Dr Katz); Harbor-UCLA Medical Center, Torrance, Calif (Dr Berman); Department of Psychiatry, New York Medical College, Valhalla (Drs Itil and Freedman); and Harvard Medical Center, Boston, Mass (Dr Schatzberg). Dr Le Bars is now with the Department of Psychiatry, New York University Medical Center, New York Institute for Medical Research; Dr Itil is now with the Department of Psychiatry, New York University Medical Center; and Dr Schatzberg is now with the Department of Psychiatry and Behavioral Sciences, School of Medicine, Stanford University, Stanford, Calif. A list of investigators appears at the end of the article.

Footnotes
Reprints: Pierre L. Le Bars, MD, PhD, New York Institute for Medical Research, 150 White Plains Rd, Tarrytown, NY 10591 (e-mail: NYI@HZI.com).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Toward Establishing Guidelines for Evaluating Cognitive Enhancement With Complementary and Alterative Medicines
Solomon and Michalczuk
Eval Health Prof 2009;32:370-392.
ABSTRACT  

Ginkgo biloba extract attenuates oxLDL-induced oxidative functional damages in endothelial cells
Ou et al.
J. Appl. Physiol. 2009;106:1674-1685.
ABSTRACT | FULL TEXT  

The 'Natural Health Service': natural does not mean safe
Dunne
Adv. Psychiatr. Treat. 2009;15:49-56.
ABSTRACT | FULL TEXT  

Effect of Topical Ginkgo biloba Extract on Steroid-Induced Changes in the Trabecular Meshwork and Intraocular Pressure
Jia et al.
Arch Ophthalmol 2008;126:1700-1706.
ABSTRACT | FULL TEXT  

Ginkgo biloba for Prevention of Dementia: A Randomized Controlled Trial
DeKosky et al.
JAMA 2008;300:2253-2262.
ABSTRACT | FULL TEXT  

Herbal Contributions to the Management of the Multi-Factorial Cognitive Disorders--Alzheimer's Disease and Vascular Dementia
Hecht
Neurophysiology and Neurogenic Speech and Language Disorders 2008;18:114-123.
ABSTRACT | FULL TEXT  

Turning over a new leaf: Ginkgo biloba in prevention of dementia?
DeKosky and Furberg
Neurology 2008;70:1730-1731.
FULL TEXT  

Evidence-based common sense?
Sherman
cfp 2008;54:166-168.
FULL TEXT  

Bon sens fonde sur des donnees probantes?
Sherman
cfp 2008;54:169-171.
FULL TEXT  

Protection against Human Immunodeficiency Virus Type 1 Tat Neurotoxicity by Ginkgo biloba Extract EGb 761 Involving Glial Fibrillary Acidic Protein
Zou et al.
Am. J. Pathol. 2007;171:1923-1935.
ABSTRACT | FULL TEXT  

EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer's disease
Tchantchou et al.
FASEB J. 2007;21:2400-2408.
ABSTRACT | FULL TEXT  

Evidence-Based Research in Complementary and Alternative Medicine III: Treatment of Patients with Alzheimer's Disease
Chiappelli et al.
Evid Based Complement Alternat Med 2006;3:411-424.
ABSTRACT | FULL TEXT  

The GuidAge study: Methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761(R) for prevention of Alzheimer disease in patients over 70 with a memory complaint.
Vellas et al.
Neurology 2006;67:S6-S11.
ABSTRACT | FULL TEXT  

Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology
Burns and O'Brien
J Psychopharmacol 2006;20:732-755.
ABSTRACT  

Effects of ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers.
Uchida et al.
J Clin Pharmacol 2006;46:1290-1298.
ABSTRACT | FULL TEXT  

Managing patients with Alzheimer's disease
Corey-Bloom et al.
PN 2006;6:78-89.
FULL TEXT  

Herbal medicine in the treatment of Alzheimer's disease
Akhondzadeh and Abbasi
AM J ALZHEIMERS DIS OTHER DEMEN 2006;21:113-118.
ABSTRACT  

Electrophysiological Analysis of the Effects of Ginkgo Biloba on Visual Processing in Older Healthy Adults
Page et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2005;60:1246-1251.
ABSTRACT | FULL TEXT  

Limited cognitive benefits in Stage +2 postmenopausal women after 6 weeks of treatment with Ginkgo biloba
Elsabagh et al.
J Psychopharmacol 2005;19:173-181.
ABSTRACT  

Mixed Dementia: Emerging Concepts and Therapeutic Implications
Langa et al.
JAMA 2004;292:2901-2908.
ABSTRACT | FULL TEXT  

Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease
Rockwood
J. Neurol. Neurosurg. Psychiatry 2004;75:677-685.
ABSTRACT | FULL TEXT  

Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT)
Gertsch et al.
BMJ 2004;328:797.
ABSTRACT | FULL TEXT  

Identification of the Adrenocorticotropin and Ginkgolide B-Regulated 90-Kilodalton Protein (p90) in Adrenocortical Cells as a Serotransferrin Precursor Protein Homolog (Adrenotransferrin)
Amri et al.
Endocrinology 2004;145:1802-1809.
ABSTRACT | FULL TEXT  

Structural Effects and Neurofunctional Sequelae of Developmental Exposure to Psychotherapeutic Drugs: Experimental and Clinical Aspects
Costa et al.
Pharmacol. Rev. 2004;56:103-147.
ABSTRACT | FULL TEXT  

Idebenone treatment fails to slow cognitive decline in Alzheimer's disease
Thal et al.
Neurology 2003;61:1498-1502.
ABSTRACT | FULL TEXT  

Early Alzheimer's Disease
Kawas
NEJM 2003;349:1056-1063.
FULL TEXT  

Ginkgo biloba Extract Inhibits Tumor Necrosis Factor-{alpha}-Induced Reactive Oxygen Species Generation, Transcription Factor Activation, and Cell Adhesion Molecule Expression in Human Aortic Endothelial Cells
Chen et al.
Arterioscler. Thromb. Vasc. Bio. 2003;23:1559-1566.
ABSTRACT | FULL TEXT  

Screening for Dementia in Primary Care: A Summary of the Evidence for the U.S. Preventive Services Task Force
Boustani et al.
ANN INTERN MED 2003;138:927-937.
ABSTRACT | FULL TEXT  

Ginkgo and Memory
Solomon and DeVeaux
JAMA 2003;289:547-548.
FULL TEXT  

Herbal Remedies
De Smet
NEJM 2002;347:2046-2056.
FULL TEXT  

Amyloid Precursor Protein, Presenilins, and alpha -Synuclein: Molecular Pathogenesis and Pharmacological Applications in Alzheimer's Disease
Suh and Checler
Pharmacol. Rev. 2002;54:469-525.
ABSTRACT | FULL TEXT  

Ginkgo for Memory Enhancement: A Randomized Controlled Trial
Solomon et al.
JAMA 2002;288:835-840.
ABSTRACT | FULL TEXT  

Achieving and Maintaining Cognitive Vitality With Aging
Fillit et al.
Mayo Clin Proc. 2002;77:681-696.
ABSTRACT  

Potential Physician Malpractice Liability Associated with Complementary and Integrative Medical Therapies
Cohen and Eisenberg
ANN INTERN MED 2002;136:596-603.
ABSTRACT | FULL TEXT  

Herbal Remedies: Drug-Herb Interactions
Kuhn
Crit Care Nurse 2002;22:22-32.
FULL TEXT  

Current Concepts in Mild Cognitive Impairment
Petersen et al.
Arch Neurol 2001;58:1985-1992.
ABSTRACT | FULL TEXT  

The use of ginkgo biloba in the treatment of dementia
Maidment
Psychiatr. Bull. 2001;25:353-356.
ABSTRACT | FULL TEXT  

Herbal Medicines and Perioperative Care
Ang-Lee et al.
JAMA 2001;286:208-216.
ABSTRACT | FULL TEXT  

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
Doody et al.
Neurology 2001;56:1154-1166.
ABSTRACT | FULL TEXT  

Herbal Therapy: What Every Facial Plastic Surgeon Must Know
Pribitkin and Boger
Arch Facial Plast Surg 2001;3:127-132.
ABSTRACT | FULL TEXT  

Efficacy of Antioxidant Therapies in Transient Focal Ischemia in Mice
Clark et al.
Stroke 2001;32:1000-1004.
ABSTRACT | FULL TEXT  

The Role of Informed Consent in the Delivery of Complementary and Alternative Medical Therapies
Cohen
Complementary Health Practice Review 2000;6:21-28.
 

Surgery and Herbal Therapy: Essential Guidelines on Bleeding, Skin Reactions, and Wound Healing
Pribitkin and Boger
Complementary Health Practice Review 2000;6:29-40.
ABSTRACT  

A Review of Herbal Medicines for Psychiatric Disorders
Beaubrun and Gray
Psychiatr. Serv. 2000;51:1130-1134.
ABSTRACT | FULL TEXT  

Antioxidant Therapy in Neurologic Disease
Delanty and Dichter
Arch Neurol 2000;57:1265-1270.
ABSTRACT | FULL TEXT  

Reactive Oxygen Species-Induced Apoptosis in PC12 Cells and Protective Effect of Bilobalide
Zhou and Zhu
J. Pharmacol. Exp. Ther. 2000;293:982-988.
ABSTRACT | FULL TEXT  

Molecular biology of Alzheimer's disease
Holmes and Wilkinson
Adv. Psychiatr. Treat. 2000;6:193-200.
FULL TEXT  

An 80-Year-Old Man With Memory Loss
Larson
JAMA 2000;283:1046-1053.
FULL TEXT  

Oxidative stress and Alzheimer disease1
Christen
Am. J. Clin. Nutr. 2000;71:621s-629s.
ABSTRACT | FULL TEXT  

Herbs in Pediatric and Adolescent Medicine
Gardiner and Kemper
Pediatr. Rev. 2000;21:44-57.
FULL TEXT  

Treatment of Alzheimer's Disease
Mayeux and Sano
NEJM 1999;341:1670-1679.
FULL TEXT  

Current and the near future medications for Alzheimer's disease: What can we expect from them?
Shua-Haim and Ross
AM J ALZHEIMERS DIS OTHER DEMEN 1999;14:294-307.
 

Dietary Supplements and Natural Products as Psychotherapeutic Agents
Fugh-Berman and Cott
Psychosom. Med. 1999;61:712-728.
ABSTRACT | FULL TEXT  

Review: Ginkgo biloba extract improves cognitive function in mild to moderate Alzheimer's disease
Bernabei
Evid. Based Ment. Health 1999;2:82-82.
FULL TEXT  

Do We Have a Treatment for Alzheimer Disease?: Yes
Gauthier
Arch Neurol 1999;56:738-739.
FULL TEXT  

Do We Have Drugs for Dementia?: No
Pryse-Phillips
Arch Neurol 1999;56:735-737.
FULL TEXT  

Confusional State in Stroke : Relation to Preexisting Dementia, Patient Characteristics, and Outcome
Henon et al.
Stroke 1999;30:773-779.
ABSTRACT | FULL TEXT  

Guideline for primary care management of dementia
Marshall et al.
BMJ 1999;318:731-731.
FULL TEXT  

The Neurobiology and Pharmacotherapy of Alzheimer's Disease
Felician and Sandson
J. Neuropsychiatry Clin. Neurosi. 1999;11:19-31.
ABSTRACT | FULL TEXT  

Herbal Therapy for Children
Turow
Pediatrics 1998;102:1492-1492.
FULL TEXT  

Medical Malpractice Implications of Alternative Medicine
Studdert et al.
JAMA 1998;280:1610-1615.
ABSTRACT | FULL TEXT  

Researching Alternatives
Sikorsk and Peters
JAMA 1998;280:1631-1631.
FULL TEXT  

Herbs as Medicines
Winslow and Kroll
Arch Intern Med 1998;158:2192-2199.
ABSTRACT | FULL TEXT  

Herbal Medicinals: Selected Clinical Considerations Focusing on Known or Potential Drug-Herb Interactions
Miller
Arch Intern Med 1998;158:2200-2211.
ABSTRACT | FULL TEXT  

Herbal Medicine for the Treatment of Cardiovascular Disease: Clinical Considerations
Mashour et al.
Arch Intern Med 1998;158:2225-2234.
ABSTRACT | FULL TEXT  

A Review of 12 Commonly Used Medicinal Herbs
O'Hara et al.
Arch Fam Med 1998;7:523-536.
ABSTRACT | FULL TEXT  

The Efficacy of Ginkgo biloba on Cognitive Function in Alzheimer Disease
Oken et al.
Arch Neurol 1998;55:1409-1415.
ABSTRACT | FULL TEXT  

Herbal Remedies in Psychiatric Practice
Wong et al.
Arch Gen Psychiatry 1998;55:1033-1044.
ABSTRACT | FULL TEXT  

Herbal Psychotropic Medications: Promises and Pitfalls
JWatch Psychiatry 1998;1998:19-19.
FULL TEXT  

Memory Loss--When Is It Alzheimer Disease?
Cullum and Rosenberg
JAMA 1998;279:1689-1690.
FULL TEXT  

New Drug Treatments for Alzheimer Disease
Larson
Arch Intern Med 1998;158:941-942.
FULL TEXT  

Other articles noted
Evid. Based Ment. Health 1998;1:36-36.
FULL TEXT  

Evaluating the Alternatives
Lin
JAMA 1998;279:706-706.
FULL TEXT  

Alternative Medicine and the Conventional Practitioner
Jonas
JAMA 1998;279:708-709.
FULL TEXT  

Ginkgo Biloba Safely Stabilizes Dementia
JWatch Psychiatry 1997;1997:3-3.
FULL TEXT  

GINKGO EXTRACT MAY STABILIZE DEMENTIA IN SOME
JWatch General 1997;1997:1-1.
FULL TEXT  

Living Longer, Aging Better: Aging Research Comes of Age
Wetle
JAMA 1997;278:1376-1377.
ABSTRACT  

The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba
Watanabe et al.
Proc. Natl. Acad. Sci. USA 2001;98:6577-6580.
ABSTRACT | FULL TEXT